Navigation Links
Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
Date:1/7/2011

clinical data described in its U.S. Biologics License to file its marketing authorization application (MAA) to the European Medicines Agency (EMA) in late 2011/early 2012.
  • To accelerate the regulatory timeline, initially PROVENGE will be manufactured through a Contract Manufacturing Organization (CMO) while Dendreon concurrently builds an immunotherapy manufacturing facility in Europe.
  • The company anticipates a regulatory decision in the first half of 2013.

  • DN24-02 IND Filing

    • Dendreon filed an Investigational New Drug (IND) application in December 2010 with the U.S. Food and Drug Administration (FDA) for DN24-02 for the treatment of invasive bladder cancer.
    • The randomized Phase 2 study will evaluate the safety and efficacy of DN24-02 in patients with HER2+ invasive transitional cell carcinoma (TCC) of the bladder following cystectomy.
    • The primary endpoint is to evaluate overall survival. Approximately 180 patients will be enrolled at clinical sites throughout the U.S.  

    Conference Call Information

    Dendreon will host a conference call today at 6:00 a.m. PT, 9:00 a.m. ET. To access the live call, dial 1-877-548-9590 (domestic) or +1-720-545-0037 (international). The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A phone replay of the call will be available for 3 days by calling 1-800-642-1687 (domestic) or +1-706-645-9291 (international); Passcode: 35063654.

    PROVENGE Indication and Safety

    PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

    PROVENGE is intended solely for autologous use and is not routinely teste
    '/>"/>

    SOURCE Dendreon Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
    2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
    3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
    4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
    6. Dendreon Reports Third Quarter 2008 Financial Results
    7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
    8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
    9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
    10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
    11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/30/2015)... Md. , March 30, 2015 CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... Food and Drug Administration (CFDA) has approved the Company,s ... in ovarian clear cell carcinoma (OCCC) patients for its ...
    (Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
    (Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
    (Date:3/29/2015)... , March 29, 2015  Caris Life Sciences® ... which Caris Molecular Intelligence®, the company,s panomic, comprehensive ... differences between several rare and difficult to treat ... have the potential to improve patient outcomes. These ... at the Society of Gynecologic Oncology (SGO) 2015 ...
    Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
    ... Readies R & D facilities for Ap3ana, CTI,s ... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ... President and COO of a Tyr Pharma and ... the Novartis Research,Foundation, has been named President of ...
    ... BioPharma,Corp. (TSX; FSE: HBP) today announced that it has ... 6,800,000 units at $1.68 per,unit, for gross proceeds totaling ... and one-half of one common share,purchase warrant, with each ... subject to adjustment, one common share at a price,of ...
    ... Investors, WILMINGTON, Del., Oct. 2 Speaking ... General Manager John Ranieri,said the company,s plans to ... on track and making significant technical progress toward ... feedstocks,economically into biofuels., "Biobutanol and cellulosic ethanol ...
    Cached Biology Technology:Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
    (Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
    (Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
    (Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
    Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
    ... obesity increasing, school administrators and public health officials are ... a study published in the November/December 2008 issue of ... researchers found that reduction or elimination of SSB from ... adolescents. Working with four schools in Maine ...
    ... to be averted, atmospheric carbon dioxide (CO2) must be reduced below ... in Open Atmospheric Science Journal by a ... and France. The authors, who include two Yale ... which civilization developed, an optimum CO2 level would be less than ...
    ... Ph.D., of the New York City Department of Health and ... be one of our body,s main protections against damage from ... of Low Radiation , Hayes explains that calcitriol, the active ... and could be used as a safe protective agent before ...
    Cached Biology News:Revised theory suggests carbon dioxide levels already in danger zone 2Could vitamin D save us from radiation? 2
    Digital display of time, vacuum and temperature , Dual vacuum control of ramping rate and ultimate level , Comes complete with RH40-12 (40 x 1.5 ml) Rotor and (2) Glass Condensation Flasks. ...
    ... DNA120 is a dedicated concentrator for efficient ... of DNA/RNA. The integrated system combines the ... The compact design, automatic pump and rotor ... time; one for heater time), makes the ...
    For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
    Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
    Biology Products: